SK Bioscience (302440) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SK Bioscience (302440) reported revenue of 651.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025651.4 billion KRW-123.5 billion KRW-56.2 billion KRW[source]
2024267.5 billion KRW-138.4 billion KRW-50.1 billion KRW[source]
2023369.5 billion KRW-12.0 billion KRW22.3 billion KRW[source]
2022456.7 billion KRW115.0 billion KRW122.5 billion KRW[source]
2021929.0 billion KRW474.2 billion KRW355.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
20252.18 trillion KRW459.6 billion KRW1.73 trillion KRW[source]
20242.15 trillion KRW373.6 billion KRW1.78 trillion KRW[source]
20231.85 trillion KRW148.0 billion KRW1.71 trillion KRW[source]
20222.14 trillion KRW399.9 billion KRW1.74 trillion KRW[source]
20212.11 trillion KRW508.8 billion KRW1.60 trillion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice